Contact Us
Drug Search Results
More Filters [+]

BAY-1817080

Alternative Names: bay-1817080, bay1817080, bay 1817080
Latest Update: 2023-07-12
Latest Update Note: Clinical Trial Update

Product Description

Eliapixant (BAY 1817080), a P2X3 receptor antagonist, in refractory chronic cough

Mechanisms of Action: P2X3 Antagonist

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Evotec
Company Location: HAMBURG 2M 22525
Company CEO:
Additonal Commercial Interests: Bayer

Clinical Description

Map of Global Clinical Trials for BAY-1817080

Countries in Clinic: Austria, Belgium, Bulgaria, Canada, China, Czech Republic, Estonia, Finland, Germany, Greece, Hungary, Italy, Latvia, Lithuania, Norway, Poland, Slovakia, Spain, United States

Active Clinical Trial Count: 4

Highest Development Phases

Phase 2: Endometriosis|Overactive Bladder

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
jRCT2031210001

P2

Completed

Endometriosis

2022-05-03

SCHUMANN

P2

Completed

Endometriosis

2022-05-03

Ovader

P2

Completed

Overactive Bladder

2022-01-21

CTR20210645

P2

Not yet recruiting

Endometriosis

None

Recent News Events

Date

Type

Title

02/04/2022

News Article

 Bayer Discontinues Clinical Development Candidate Eliapixant (BAY1817080), Evotec Regains the Rights to all P2X3 Assets

07/19/2021

News Article

 Chronic Refractory Cough Market Size To Experience Subsequent Growth at a CAGR of 6.57% During the Study Period 2018-2030

03/11/2021

News Article

 Chronic Refractory Cough Market - Market Insight, Epidemiology and Market Forecast - 2030 - ResearchAndMarkets.com

07/23/2020

News Article

 Insights on the H1 2020 Pipeline Review for P2X Purinoceptor 3 - ResearchAndMarkets.com

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions